2024/05/03 19:30:23 | |
---|---|
Price | |
0.392 EUR | |
Difference | 0.13% (0.00) |
ISIN | NL0014040206 |
Symbol | CNTG |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 12 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 0.391 EUR |
High | 0.401 EUR |
Low | 0.391 EUR |
Close (prev. day) | 0.3915 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 7 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/04/26 | Global Equity Ratings | ||
2024/04/03 | Global Equity Ratings | ||
2024/03/13 | Global Equity Ratings | ||
2024/02/22 | Global Equity Ratings | ||
2024/02/14 | Global Equity Ratings |
2024/05/03 19:30:23 | |
---|---|
Price | |
0.392 EUR | |
Difference | 0.13% (0.00) |
ISIN | NL0014040206 |
Symbol | CNTG |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 12 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 0.391 EUR |
High | 0.401 EUR |
Low | 0.391 EUR |
Close (prev. day) | 0.3915 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 7 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -65.76% | -37.97% | -95.44% |
Perf (abs.) | -0.75 | -0.24 | -8.21 |
Beta | 0.51 | 1.03 | 0.69 |
Volatility | 68.31 | 98.70 | 102.55 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.408 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.522 EUR (44) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.790 EUR (14) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.901 EUR (17) |
YTD High | date | 1.130 EUR (2024/01/18) |
YTD Low | date | 0.391 EUR (2024/05/03) |
52 Weeks High | date | 1.545 EUR (2023/06/28) |
52 Weeks Low | date | 0.391 EUR (2024/05/03) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/05/03 | 22:26 | 0.406 EUR | 0.00 | 1 |
Stuttgart | 2024/05/03 | 19:26 | 0.3715 EUR | 0.00 | 8 |
Nasdaq | 2024/05/03 | 22:30 | 0.4429 USD | 0.00 | 54 |
Hamburg | 2024/05/03 | 08:16 | 0.39 EUR | 0.00 | 3 |
Frankfurt | 2024/05/03 | 08:15 | 0.43 EUR | 0.00 | 1 |
Duesseldorf | 2024/05/03 | 19:30 | 0.392 EUR | 0.00 | 7 |
Berlin | 2024/05/03 | 20:30 | 0.4125 EUR | 0.00 | 18 |
CENTOGENE NV |
- - |
Am Strande 7 - 18055 Rostock |
Telefon: +49-381-80113400 |
Fax: +381-80113401 |
E-mail: - |
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark. |
Kim Stratton | Chairman of Managing Board |
Bettina Goerner | Member of Executive Committee |
Ian Rentsch | Member of Executive Committee |
Miguel Coego Rios | Member of Executive Committee |
Patrice P. Denèfle | Member of Executive Committee |
Peter Bauer | Member of Executive Committee |
Peer Schatz | Chairman of Supervisory Board |
Eric Souêtre | Member of Supervisory Board |
Flemming Ørnskov | Member of Supervisory Board |
Hubert Birner | Member of Supervisory Board |
Jonathan Sheldon | Member of Supervisory Board |
Guido Prehn | Member of Supervisory Board |
Mary Sheahan | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer